A 32-year-old man with a history of genital herpes presents with recurrent lesions on the penile shaft for the third time in 6 months. He reports prodromal tingling and burning for 12 hours before vesicles appeared. On examination, grouped vesicles and erosions are seen. He is otherwise healthy and immunocompetent. Which of the following is the most appropriate management strategy for this recurrent episode?

Explanation

## Diagnosis and Rationale This is a **recurrent episode of genital herpes** with: - Prior history of genital herpes - Prodromal symptoms (tingling, burning) preceding vesicles - Grouped vesicles and erosions on genital skin - Immunocompetent host - Frequency: 3 episodes in 6 months (moderate recurrence rate) ## Management of Recurrent Genital Herpes **Key Point:** Recurrent episodes are milder and shorter than primary infection. Short-course high-dose therapy initiated during prodrome is the standard approach for episodic recurrences [cite:Harrison 21e Ch 187]. **High-Yield:** Oral acyclovir 800 mg three times daily for 2 days (or valacyclovir 500 mg twice daily for 3 days) initiated during prodrome is first-line for episodic recurrent genital herpes in immunocompetent patients. ## Episodic vs. Suppressive Therapy | Feature | Episodic Therapy | Suppressive Therapy | |---------|---|---| | **Indication** | ≤6 recurrences/year; patient-initiated at prodrome | ≥6 recurrences/year; or frequent/severe episodes; or high transmission risk | | **Regimen** | Acyclovir 800 mg TDS × 2 days (or valacyclovir 500 mg BD × 3 days) | Acyclovir 400 mg BD indefinitely (or valacyclovir 500 mg OD) | | **Efficacy** | Reduces episode duration by ~1 day if started during prodrome | Reduces recurrence frequency by 70–80%; reduces asymptomatic shedding | | **When to Start** | At first sign of prodrome (tingling, burning) | Daily, regardless of symptoms | | **Duration** | 2–3 days | Indefinite; reassess annually | **Clinical Pearl:** The window for episodic therapy is narrow—it must be initiated during prodrome (within 12 hours of symptom onset) to be effective. Once vesicles have appeared, benefit is minimal. This patient should keep acyclovir on hand for rapid initiation. ## Why NOT Suppressive Therapy for This Patient? - **Recurrence frequency**: 3 episodes in 6 months = 6/year at current rate—borderline for suppression - **Patient preference**: Many patients prefer episodic therapy to avoid daily medication - **Cost and side effects**: Suppressive therapy requires long-term commitment - **Indication for suppression**: Reserved for ≥6 recurrences/year, severe episodes, immunocompromised hosts, or discordant couples **Mnemonic: SUPPRESS** — Suppressive therapy indicated when **S**evere/frequent (≥6/year), **U**ndergoing immunosuppression, **P**regnant (to prevent neonatal herpes), **P**artner-discordant, **R**ecurrent (≥6/year), **E**rosive/extensive lesions, **S**ystemic symptoms, **S**exually active with multiple partners. ## Dosing for Episodic Recurrence **Acyclovir options:** - 800 mg three times daily for 2 days (preferred) - 400 mg five times daily for 5 days (alternative) **Valacyclovir (prodrug of acyclovir):** - 500 mg twice daily for 3 days (equivalent efficacy, better bioavailability) - 1000 mg twice daily for 5 days (alternative) **Famciclovir:** - 125 mg three times daily for 5 days (alternative) ## Supportive Care - Analgesia as needed - Sitz baths - Avoid sexual contact during active lesions - Patient education on prodrome recognition for early treatment